Navigation Links
ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
Date:12/15/2011

YOKOHAMA, Japan, December 15, 2011 /PRNewswire/ --

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year.

Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized.  ReproCELL is anticipating its commercialization in Q2 2012. Prior to the launch, sample of the cells will become available for testing to pharmaceutical and biotech companies in January 2012.

ReproCELL is a world-leading pioneer in commercializing human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched iPS cell derived cardiomyocytes in April 2009 for cardiac toxicity testing, followed by the launch of iPS cell derived neuronal cells in October 2010 for efficacy screening of neuroactive compounds.

ReproCELL's Representative Director and CEO, Chikafumi Yokoyama PhD commented, "We are pleased to see iPS cell-derived hepatocytes showing the highest level of quality ever seen, expressing the same qualities as that of primary human hepatocytes currently used by the pharmaceutical industry, including drug metabolizing enzyme activity. We can expect to see its early adoption for drug toxicity and pharmacokinetic studies."

Aspects of NIBIO's technology on the induction of iPS cell-derived hepatocyte differentiation can be found in the following publication:

Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction.

Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H., Mol Ther. 2011 Nov 8. [Epub ahead of print] PMID: 22068426

Company:  ReproCELL Inc.
Representative: Chikafumi Yokoyama PhD,
Contact:  info_repro@reprocell.com   Tel:+81-(0)45-475-3887
KDX Shin-Yokohama 381 bldg. 8F, 3-8-11 Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa 222-0033, Japan



'/>"/>
SOURCE ReproCELL Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells
2. SK Life Sciences has Licensed Pristima
3. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
4. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
5. Full Agenda Announced for CMAC 2011 - CBIS 2nd Annual Commercialization and Market Access Congress
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
8. Saladax Biomedical, Inc. Announces European Commercialization Team
9. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research and ... has announced the addition ... - Material, Application - Forecast to 2025" report to ... The report provides a detailed analysis on current ... Market forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, LLC, ... and medical device manufacturers and regulators, is proud to announce the worldwide release ... client designed to provide product vigilance departments with the flexibility and ease of ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American ... to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said ... to the existing policy. AMIA recommended that NIH earmark funding for researchers to ...
Breaking Biology Technology:
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
Breaking Biology News(10 mins):